US OptionsDetailed Quotes
TVTX240920C12500
- 0.90
- -0.10-10.00%
15min DelayClose Sep 10 16:00 ET
0.91High0.60Low
0.80Open1.00Pre Close400 Volume2.11K Open Interest12.50Strike Price31.86KTurnover69.53%IV4.36%PremiumSep 20, 2024Expiry Date0.34Intrinsic Value100Multiplier10DDays to Expiry0.56Extrinsic Value100Contract SizeAmericanOptions Type0.6189Delta0.2586Gamma16.57Leverage Ratio-0.0299Theta0.0020Rho10.25Eff Leverage0.0081Vega
Travere Therapeutic Stock Discussion
👀 stay tuned for updates on meeting outcomes
See 👇 for further info.
🚨 This Week’s AdCom:
$Iterum Therapeutics (ITRM.US)$ : Meeting ongoing 🤔
⇨ Sulopenem
‣ uUTI (Uncomplicated Urinary Tract Infection)
‣ AdCom: 9/9/24
🚨 Last Week’s PDUFAs:
$Travere Therapeutic (TVTX.US)$ : Approved 9/5 🎉
⇨ FILSPARI (Sparsentan)
‣ IgA nephropathy (IgAN)
‣ PDUFA: 9/5/24
$Avadel Pharmaceuticals (AVDL.US)$ : Awaiting decision 🤔
⇨ LUMRYZ (sodium oxybate)
‣...
🤔 no action even for AH.
1 min ago
Travere Therapeutics Announces Full FDA Approval of Filspari® (Sparsentan), the Only Non-Immunosuppressive Treatment That Significantly Slows Kidney Function Decline in Iga Nephropathy
No comment yet